CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. Reply
- PMID: 34706181
- DOI: 10.1056/NEJMc2114592
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. Reply
Comment on
-
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.N Engl J Med. 2021 Oct 28;385(18):1721-1722. doi: 10.1056/NEJMc2114592. N Engl J Med. 2021. PMID: 34706179 No abstract available.
-
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.N Engl J Med. 2021 Oct 28;385(18):1722. doi: 10.1056/NEJMc2114592. N Engl J Med. 2021. PMID: 34706180 No abstract available.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials